| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Howard Hughes Medical Institute, Department of Biochemistry and Cell Biology, Rice University, Houston, TX 77005; and
Department of Rheumatology, Rheumatology Research Group, University of Birmingham/Medical Research Council Centre for Immune Regulation, Medical School, University of Birmingham, Birmingham, West Midlands, United Kingdom
Wound healing and the dysregulated events leading to fibrosis both involve the proliferation and differentiation of fibroblasts and the deposition of extracellular matrix. Whether these fibroblasts are locally derived or from a circulating precursor population is unclear. Fibrocytes are a distinct population of fibroblast-like cells derived from peripheral blood monocytes that enter sites of tissue injury to promote angiogenesis and wound healing. We have found that CD14+ peripheral blood monocytes cultured in the absence of serum or plasma differentiate into fibrocytes within 72 h. We purified the factor in serum and plasma that prevents the rapid appearance of fibrocytes, and identified it as serum amyloid P (SAP). Purified SAP inhibits fibrocyte differentiation at levels similar to those found in plasma, while depleting SAP reduces the ability of plasma to inhibit fibrocyte differentiation. Compared with sera from healthy individuals and patients with rheumatoid arthritis, sera from patients with scleroderma and mixed connective tissue disease, two systemic fibrotic diseases, were less able to inhibit fibrocyte differentiation in vitro and had correspondingly lower serum levels of SAP. These results suggest that low levels of SAP may thus augment pathological processes leading to fibrosis. These data also suggest mechanisms to inhibit fibrosis in chronic inflammatory conditions, or conversely to promote wound healing.
This article has been cited by other articles:
|
|
 |
|
  A. P. Castano, S.-L. Lin, T. Surowy, B. T. Nowlin, S. A. Turlapati, T. Patel, A. Singh, S. Li, M. L. Lupher Jr., and J. S. Duffield Serum Amyloid P Inhibits Fibrosis Through Fc{gamma}R-Dependent Monocyte-Macrophage Regulation in Vivo Science Translational Medicine, November 4, 2009; 1(5): 5ra13 - 5ra13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Strieter, E. C. Keeley, M. A. Hughes, M. D. Burdick, and B. Mehrad The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis J. Leukoc. Biol., November 1, 2009; 86(5): 1111 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Galligan, K. A. Siminovitch, E. C. Keystone, V. Bykerk, O. D. Perez, and E. N. Fish Fibrocyte activation in rheumatoid arthritis Rheumatology, October 25, 2009; (2009) kep265v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Niedermeier, B. Reich, M. R. Gomez, A. Denzel, K. Schmidbauer, N. Gobel, Y. Talke, F. Schweda, and M. Mack CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes PNAS, October 20, 2009; 106(42): 17892 - 17897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Haudek, J. Trial, Y. Xia, D. Gupta, D. Pilling, and M. L. Entman Fc receptor engagement mediates differentiation of cardiac fibroblast precursor cells PNAS, July 22, 2008; 105(29): 10179 - 10184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Shao, R. Suresh, V. Vakil, R. H. Gomer, and D. Pilling Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation J. Leukoc. Biol., June 1, 2008; 83(6): 1323 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Rosenberg Cytokines and fibrocyte differentiation--altering the balance: an interview with Dr. Darrell Pilling J. Leukoc. Biol., June 1, 2008; 83(6): 1334 - 1335. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kisseleva and D. A. Brenner Mechanisms of Fibrogenesis Experimental Biology and Medicine, February 1, 2008; 233(2): 109 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Gomperts and R. M. Strieter Fibrocytes in lung disease J. Leukoc. Biol., September 1, 2007; 82(3): 449 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Scheja, K. Larsen, L. Todorova, E. Tufvesson, M. Wildt, A. Akesson, L. Hansson, S. Ellis, and G. Westergren Thorsson BALF-derived fibroblasts differ from biopsy-derived fibroblasts in systemic sclerosis Eur. Respir. J., March 1, 2007; 29(3): 446 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Haudek, Y. Xia, P. Huebener, J. M. Lee, S. Carlson, J. R. Crawford, D. Pilling, R. H. Gomer, J. Trial, N. G. Frangogiannis, et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice PNAS, November 28, 2006; 103(48): 18284 - 18289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Pilling, N. M. Tucker, and R. H. Gomer Aggregated IgG inhibits the differentiation of human fibrocytes J. Leukoc. Biol., June 1, 2006; 79(6): 1242 - 1251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Frid, J. A. Brunetti, D. L. Burke, T. C. Carpenter, N. J. Davie, J. T. Reeves, M. T. Roedersheimer, N. van Rooijen, and K. R. Stenmark Hypoxia-Induced Pulmonary Vascular Remodeling Requires Recruitment of Circulating Mesenchymal Precursors of a Monocyte/Macrophage Lineage Am. J. Pathol., February 1, 2006; 168(2): 659 - 669. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
